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Microglia Activation In Alzheimer’s Disease
Kirk Phillip Townsend
ABSTRACT
The work detailed in this dissertation has an overarching theme of modulating
microglia activation in both in vivo and in vitro models relevant to AD. The premise is
that understanding microglia function in this context may lead to a better understanding
of AD pathogenesis and thus to effective therapeutic interventions. In chapter 3, we
employ a well-defined model of microglia activation whereby the intraperitoneal delivery
of LPS results in CNS microglia activation and TNF-α production. Having previously
identified that CD45 signaling pathways antagonized microglia TNF-α production in
vitro and given that immunotherapy with anti-CD45 antibodies are already in clinical
trials for both the treatment of malignant disorders as well as for tolerance induction
following organ transplants, we investigated whether microglial CD45 could be a
relevant molecular target in the opposition of microglia activation in vivo.
Given that a number of epidemiological studies have shown an inverse correlation
between the use of statins (a class of drugs that were initially described as specific
inhibitors of cholesterol biosynthesis) and the incidence of Alzheimer’s disease
(Wolozin, 2000; Simon 2002; Zamrini, 2004); in chapter 4, we employed one of the most
prescribed statins, lovastatin, in our microglia activation paradigm. Interestingly, we
vii

show that statins not only inhibit the enzyme HMG-CoA (the rate limiting step of
cholesterol biosynthesis), but that they also display pleiotrophic effects including the
inhibition of CD40 expression. Given the role of CD40 in microglia activation and its
potential role in AD pathogenesis, we investigated whether lovastatin’s protection in AD
might be derived from effects on microglia function as governed by the CD40 pathway.
In chapter 5, we provide evidence for a model of microglia activation that addresses
some of the current controversies concerning the role of microglia cells in AD
pathogenesis. The model suggests that microglia cells exist in a number of distinct
activation states (one such states we denote the “phagocytic state”) microglia function to
clear cellular debris or foreign invaders, or in the case of AD, to remove β-amyloid/Aβ
peptides. However, in response to certain co-stimuli (i.e. CD40 activation) these
microglia take the form of an “antigen presenting cell” (APC) whereby they lose their
phagocytic capacity in lieu of cytokine production and thus potentially contribute to AD
pathogenesis.
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CHAPTER ONE
INTRODUCTION

1.1

Epidemiology of Alzheimer’s disease
Originally described by Alois Alzheimer in 1906, Alzheimer's disease (AD) has

emerged as the most common type of dementia in the elderly today. Although the
definitive diagnosis of AD requires histological confirmation, the clinician may establish
the diagnosis antemortem, with a fair degree of certainty, based on the clinical findings of
a gradually progressive cognitive decline that results in the loss of memory, language
skills, and activities of daily living.
As of 2003, approximately 4.5 million people in the United States were clinically
diagnosed with AD and this figure is expected to triple by the year 2050 according to the
National Institutes of Health. This prevalence is due in part to the fact that aging presents
a strong risk factor for developing AD for example, at age 60 the likelihood of
developing AD is estimated to be 1%; however, the risk doubles every five years
reaching 30-50% by the age of 85. Interestingly, even after statistical correction for
longevity, women are affected with AD at a ratio of 2:1 compared to men (Corder, 2004).
Recent research suggests that the hormone estrogen can be neuroprotective and its
reduction in post-menopausal women might increase their risk of developing AD.
Although AD pathogenesis is multifactorial, genetic risk factors are clearly involved.
The two basic types of AD are familial and sporadic. The familial AD (FAD) is an early1

onset form (meaning the disease develops before age 65) that comprises less than 10 % of
AD patients. The FAD etiology is caused by gene mutations on chromosomes 1
(Presenilin-2), 14 (Presenilin-1), and 21 (Amyloid Precursor Protein) all of which lead to
increased Aβ peptide production and/or its deposition in the CNS. The sporadic form of
AD (having no known cause or obvious inheritance pattern) constitutes the majority of
cases, with onset usually developing after age 65. Although a specific gene has not been
identified as the cause of late-onset AD, genetic factors do appear to play a role in the
development of this form of AD. Genetic association and linkage studies have shown
that the apolipoprotein E (ApoE) gene, found on chromosome 19, is one risk factor gene
identified with an increased risk of developing late-onset AD. This gene codes for a
protein that helps carry cholesterol in the bloodstream. The APOE gene has several
alleles APOE e2, e3 and e4. The ApoE4 genotype is associated with an increased risk for
late-onset AD, while the ApoE2 seems to confer protection. Consistent with a
multifactorial etiology, ApoE status alone does not serve as a sufficient screening tool as
it cannot definitively predict which carriers will develop AD, when onset will occur or
the severity of the disease course.

1.2

Sign and Symptoms
While short-term memory impairment is often the presenting symptom, remote

memory loss also appears to be affected over time. Another important feature of AD is
the disturbance of language. Initially, AD patients may search for words when naming
objects or while engaged in a simple conversation. With progression of the disease,
however, the language difficulties evolve into a communication breakdown as the patient
2

struggles with a markedly limited vocabulary, nominal aphasia, echolalia, and defects in
verbal comprehension.
Behavioral problems emerge throughout the various stages of the disease. Mood
disturbances such as depression, anxiety, or apathy may be present early on in AD, while
delusions, hallucinations, and psychosis can be prominent in later stages. In addition,
aggression and inappropriate sexual behavior can be particularly problematic for the
caregiver.
In advanced stages of AD, patients may exhibit extrapyramidal signs such as
tremor and gait disturbance, frontal lobe release phenomena, urinary incontinence and
myoclonus. Seizures can also be seen in some patients with late stage disease. Finally,
patients with end-stage AD almost invariably enter a vegetative-like state as all cognitive
activity ceases.

1.3

Diagnosis
In 1984 the National Institute of Neurological and Communicative Disorders and

Stroke and the Alzheimer's Disease and Related Diseases Association (NINCDS-ARDA)
established diagnostic criteria designed for research purposes and clinical definition
(McKhann, 1984). Now recommended by the American Academy of Neurology (AAN)
for the diagnosis of AD, this classification is divided into definite, probable, and possible
AD (Knopman , 2001).
In addition to histopathological confirmation, definite AD requires the clinical
finding of dementia as determined by the Mini-Mental Status Exam (MMSE) or other
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standardized neuropsychological testing; the exam must demonstrate deficits in two or
more areas of cognition with progressive memory loss in the absence of delirium.
Probable AD is the clinical determination of dementia as described above and is
supported by the findings of impaired activities of daily living, loss of specific cognitive
functions such as language and motor skills, and a family history. Other clinical findings
that support the diagnosis in patients with advanced AD are myoclonus, gait disorder, and
increased muscle tone. Possible AD is considered when there is variation in the onset,
presentation, or clinical course of the dementia and when a second brain disease or
systemic disorder is present. Clinical factors that make the diagnosis of AD unlikely
include sudden onset and focal neurological findings such as hemiparesis and visual field
deficits. Clinically, both the NINCDS-ADRDA criteria and the Diagnostic and
Statistical Manual of Mental Disorders IIIR definition of Dementia of the Alzheimer
Type (DAT) may be used to diagnose AD with 90% accuracy (Knopman, 2001).

1.4

Treatment

1.4.1 Management of Cognition
Currently there is no cure for AD, available treatments only transiently improve
memory and cognition. As of 2004, there are only five FDA-approved drugs currently
available for use in AD therapy as outlined in Table I. In patients with mild to moderate
disease, the mainstays of treatment are the acetylcholinesterase inhibitors, which are
aimed at increasing acetylcholine levels throughout the CNS.

4

TABLE 1.1
FDA approved treatments for Alzheimer’s disease
Donepezil
Aricepts™
cholinesterase inhibitors
Improves cognition, global function, and
activities of daily living.
Exelon™
Rivastigmine tartrate
It improves cognition, participation in activities
of daily living, and global evaluation ratings in patients with mild to moderately severe
Alzheimer's disease.
Galantamine
Reminyl™
cholinesterase inhibitor
Improve cognitive function in mild/moderate
AD.
Memantine
Ebixa™, Namenda™
NMDA receptor antagonist
Improves cognitive, social and motor
impairment.
Tacrine
Cognex™
Acetylcholinesterase inhibitor
Increase cognition in mild to moderately
demented Alzheimer's disease.

5

In addition to the use of cholinesterase inhibitors, vitamin E and selegiline may
also be of benefit in the pharmacologic treatment of AD (Doody, 2001). These
antioxidant agents are thought to provide some degree of neuroprotection and in a clinical
study slowed disease progression by 25% over placebo (Sano, 1997). However, clinical
judgment needs to be carefully exercised when prescribing selegiline for AD patients, as
the side-effect profile of the mono-amine oxidase inhibitor may outweigh the benefit of
its use. Estrogen, the acetylcholine precursor lecithin, nicotine, and muscarinic agonists
have not shown any significant benefit in past clinical trials and are not approved for
treatment.

1.4.2 Management of Non-cognitive Symptoms
Depression is common in patients with AD and may require pharmacologic
treatment. Serotonin reuptake inhibitors are relatively well tolerated by patients and are
preferred over tricyclic antidepressants, which can often exacerbate the cognitive
impairment due to its anticholinergic properties. The occurrence of behavioral
disturbances such as psychosis and agitation requires an investigation for a correctable
underlying cause such as a urinary tract infection before a neuroleptic agent should be
considered. If there is no external etiology, then the establishment of a quiet, controlled,
and familiar environment for the patient can help to decrease confusion and
disorientation.
Special care units within long-term care facilities may be considered as some
studies have shown a reduced need for anti-psychotics and physical restraints as well as a
decrease in behavioral disturbances in AD patients who reside there (Doody, 2001).
6

Finally, psychosocial intervention for the caregiver is an integral part of managing
patients with AD. Education, support groups, and respite care services are invaluable to
family members and friends who provide the primary care for AD patients (Haley, 1997).

1.5

Pathophysiology of Alzheimer’s disease
Although imaging technologies are rapidly developing to determine the extent of

β-amyloid plaque burden in the living patient with the intent of diagnosing, monitoring
treatment effectiveness and/or following disease progression, current criteria limits a
definite diagnosis of AD to postmortem brain examination. The hallmark
neuropathological findings in the AD brain include: β-amyloid plaques; neurofibrillary
tangles; and neuronal cell death. Additional pathological findings include CNS
inflammation and gliosis (both microglial and astrocytic).

1.5.1 β-Amyloid Plaques
β-amyloid plaques are extracellular proteinaeous aggregrates principly found in
the hippocampus and frontal cortex of AD sufferers. These β-amyloid plaques or senile
plaques may be classified further according to their size, density and composition, but the
common feature is that they all contain isoforms of the amyloid-β protein (Aβ). Aβ is a
39-42 amino acid peptide that is formed by the proteolytic cleavage of its parent molecule
β-amyloid precursor protein (APP) by enzymes “referred to as secretases”. Several lines
of evidence suggest that Aβ deposition in the CNS may be central to the pathogenesis of
AD. For instance, specific mutations in the APP gene as well as its secretases have been
identified in patients with the familial form of AD (Moran, 1995). Furthermore, the APP
7

gene resides on chromosome 21 and the increase in gene dosage seen in the trisomy
disorder of Down's syndrome has been correlated with over-expression of the APP
mRNA in the Down’s syndrome brains (Lendon, 1997). Importantly, individuals with
Down syndrome (by 40 years of age) develop virtually all of the morphological,
neurodegenerative, and biochemical changes observed in AD brains, including β-amyloid
plaques and neurofibrillary tangles (Howard, 1995). These findings form the basis of
‘the amyloid hypothesis” of AD pathogenesis, which states that the elevated CNS levels
of Aβ and its development into amyloid plaques leads to neurodegeneration as evidenced
by neurofibrillary tangle formation. Although the amyloid hypothesis is arguably the
most prevalent explanation for AD disease, it is not without its weaknesses, evidenced
primarily by the poor correlation between the concentrations and distribution of amyloid
depositions in the brain and several parameters of AD pathology, including degree of
dementia, loss of synapses, loss of neurons and abnormalities of the cytoskeleton.
Furthermore, although transgenic mouse models that harbor familial AD forms of human
APP and/or PS1 do display copious amounts of β-amyloid plaques in their brains, there is
no obvious effect on neuron function or viability suggesting that although Aβ peptides
may be the trigger for the neurodegenerative events seen in the AD brain, the
downstream neurotoxic effector function lies elsewhere. Interestingly, animal models
that express human tau protein do in fact manifest significant neuron cell loss in the
absence of amyloid deposits (Zhang, 2004).

1.5.2 Neurofibrillary Tangles

8

Neurofibrillary tangles examined at the electron microscopy level reveal an array
of paired helical filaments which biochemical analysis has shown to be composed
principly of the protein tau. Tau is an important cytoskeletal protein, which in the neuron
is essential for axonal growth and remodeling. However, when hyper-phosphorylated the
tau protein forms tangles that are systematically deposited within neurons located in the
hippocampus and medial temporal lobe, the parieto-temporal region, and the frontal
association cortices ultimately leading to cell death. A putative link between β-amyloid
plaque deposition and neurofibrillary tangle formation is a central point of the β-amyloid
hypothesis, yet finding the cellular and/or molecular signaling pathways that bridges
these two pathological features remains an area of intense research. Interestingly, CNS
areas involved with β-amyloid plaques are not strictly mirrored by neurofibrillary tangle
formation, but areas of neuronal cell death and synapse loss have a similar distribution
pattern as the neurofibrillary tangles.

1.5.3 Inflammation and Gliosis
The exact role of inflammation in the pathogenesis of AD is still controversial.
At the cellular level, this inflammation is evidenced (upon post-mortem examination) by
the presence of microglia and astrocytes around the β-amyloid plaques (Alzheimer, 1907;
Akiyama, 1994). This has been recently interpreted to represent microglia phagocytic
clearance or astrocytes “walling off” of the β-amyloid plaques. Besides their phagocytic
role microglia can also produce pro-inflammatory molecules, which is part of the
armamentarium to deal with invading organisms. This dual role of the activated
microglia has led to the various hypotheses regarding their involvement in AD. On one
9

hand, the microglia dysfunction hypothesis suggests that the senescence of microglia
leads to accumulation of β-amyloid plaques due to the loss of their powerful clearance
mechanisms. On the other hand, chronic microglia activation leading to elevated
proinflammatory products has been shown to mediate neurotoxicity in vitro. At the
molecular level differential display, gene array, as well as protein studies, have suggested
that various pro-inflammatory molecules are elevated in the AD brain compared to agematched cognitive normal controls. Moreover, epidemiological studies have shown that
the use of non-steroidal anti-inflammatory drugs (NSAIDS) are associated with a
decreased risk for developing AD. However, a number of prospective clinical trials
evaluating the use of drugs targeting various aspects of the immune system such as
prednisone, hydroxycholoroquine, and selective COX-2 inhibitors have only been able to
demonstrate marginal benefits (Jones, 2001). Recently, it has been reported that the
NSAIDS inhibit γ-secretase activity and thereby Aβ production (Beher, 2004), suggesting
the possibility of direct effect of NSAIDS on APP metabolism independent of the
modulation of the CNS inflammatory milieu.

10

CHAPTER TWO
MATERIALS AND METHODS

2.1 Peptides and drugs.
2.1.1 Cy3-Aβ peptide preparation
The Cy3-Aβ peptides conjugation was carried out with strict accordance to
manufacturers described protocols. Briefly, Aβ1-42 was dissolved in 0.15 M sodium
chloride and Cy3TM mono-reactive NHS ester (Amersham Biosciences, Piscataway, NJ)
was diluted in dimethyl sulfoxide (DMSO) to a working concentration of 10 mg/ml and
this was slowly added to the Aβ1-42 solution while stirring. The Cy3-Aβ1-42 solution was
protected from light while it was stirred for 45 min at room temperature. To separate the
free Cy3-dye, the solution was dialyzed against 1L of 0.15 M sodium chloride for 4 h at
room temperature. The solution was then exchanged with fresh 0.15 M sodium chloride
and dialyzed overnight at 4°C. The next day the Cy3-Aβ1-42 solution was dialyzed
against 1L of 0.1 M PBS for 4 h at room temperature, and again dialyzed overnight using
fresh 0.1 M PBS. The solution was then filtered through a 0.22 µm syringe and the
eluate was aliquoted and stored at –20°C until use.

2.1.2 Antibodies and recombinant proteins
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Lovastatin was obtained from Sigma (St Louis, MO) and dissolved in DMSO (1%) to a
stock concentration of 25 mM. Mouse anti-human Aβ monoclonal antibody, clone
BAM-10, was purchased from Sigma (St. Louis, MO). Aβ1-42 and FITC-conjugated Aβ142

peptides were obtained from QCB/Biosource International (Camarillo, CA). Human

soluble recombinant CD40L protein was purchased from Alexis Biochemicals (San
Diego, CA). Recombinant proteins (IFN-γ, TNF-α, IL-4 and IL-10) were purchased
from R&D Systems. Purified rat anti-mouse MHC class II antibody was obtained from
PharMingen (San Diego, CA). The anti-mouse and anti-rabbit HRP-conjugated second
antibodies were purchased from New England Biolabs (Beverly, MA). Immun-Blots™
polyvinylidene difluoride membranes and the Immun-Star™ chemiluminescence
substrate were purchased from Bio-Rad (Hercules, CA).

2.2 Primary murine microglia cell cultures
Breeding pairs of C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor,
ME) and housed in the animal facility at the University of South Florida Health Science
Center. Murine primary culture microglial cells were isolated from mouse cerebral
cortices and were grown in RPMI medium supplemented with 5% fetal calf serum, 2 mM
glutamine, 100 units/mL penicillin, 0.1 mg/mL streptomycin, and 0.05 mM 2mercaptoethanol according to previously described methods (Tan, 1999). Briefly,
cerebral cortices from newborn mice (1-2 days old) were isolated under sterile conditions
and were kept at 4ºC prior to mechanical dissociation. Cells were plated in 75-cm2
flasks, and complete medium was added. Primary cultures were kept for 14 days so that
only glial cells remained, and microglial cells were isolated by shaking flasks at 200 rpm
12

in a Lab-Line™ Incubator-Shaker. More than 98% of these glial cells stained positive for
MAC-1 (CD11b/CD18; Boehringer Mannheim, Indianapolis, IN). Additionally, between
85% and 95% of microglial cells stained positive for CD45 by fluorescence-activated cell
sorter (FACS) analysis as described previously (Tan, 1999).

2.3 Microglial phagocytosis assay
2.3.1 Using fluorometric detection of FITC-Aβ
For fluorometic analysis, primary murine microglial cells were seeded at 1 x 105
cells/well (n = 6 for each condition) in 24-well tissue-culture plates containing 0.5 mL of
complete medium (RPMI 1640 medium supplemented with 5% fetal calf serum). These
cells were treated for 15, 30 and 60 min with “aged” Aβ1-42 conjugated with FITC
(supplied by Biosource International, used at 300 nM dissolved in dH20 and preincubated for 24 h at 37oC) (Chung, 1999). In the presence of FITC-Aβ1-42, microglial
cells were then co-treated with CD40L or control (heat-inactivated CD40L protein, 2
µg/mL). Some of these cells were treated with “aged” FITC-Aβ1-42 in the presence of
cytokines (including TNF-α, IFN-γ, IL-4 and IL-10) for 60 min. In addition, in parallel
24-well tissue-culture plates, microglial cells were incubated at 4oC with FITC-Aβ1-42
with or without various combinations of CD40L or cytokines. Microglial cells were then
rinsed 3 times in Aβ-free complete medium, and the media were exchanged with fresh
Aβ-free complete medium for 10 min both to allow for removal of non-incorporated Aβ
and to promote concentration of the Aβ into phagosomes. Extracellular and cell
associated FITC-Aβ were quantified using a MFX 96-well microplate fluorometer
(Molecular Devices Corp., Sunnyvale, CA) with an emission wavelength of 538 nm and
13

an excitation wavelength of 485 nm. A standard curve from 0 nM to 500 nM of FITCAβ was run for each plate. Total cellular proteins were quantified using the Bio-Rad
protein assay. The mean fluorescence values for each sample at 37ºC and 4ºC at the
indicated time points were determined by fluorometic analysis. Relative fold change
values were calculated as: (mean fluorescence value for each sample at 37ºC/mean
fluorescence value for each sample at 4ºC). In this manner, both extracellular and cell
associated FITC-Aβ were quantified. (b) For fluorescence microscope examination,
primary microglial cells (seeded in 24-well tissue-culture plates) were treated with preaggregated PE-Aβ1-42 (50 nM) in the presence or absence of CD40L (2 µg/mL) at 37oC
for 60 min. In addition, in parallel 24-well tissue-culture plates, microglial cells were
incubated at 4oC with PE-conjugated Aβ (50 nM) with or without CD40L (2 µg/mL) for
60 min. Following treatment, these cells were washed 5 times with ice-cold PBS to
remove extracellular Aβ and then stained with FITC-anti-mouse MHC II antibody (2
µg/mL; PharMingen) at 4oC for 15 min. After washing 3 times with ice-cold PBS, these
cells were fixed in 4% paraformaldehyde, mounted, and then viewed under an Olympus
IX71/IX51 fluorescence microscope equipped with a digital camera system. (c) For
Western blot examination, primary cultured microglial cells were treated with CD40L (2
µg/mL) in the presence or absence of pre-aggregated Aβ1-42 (3 µM) for 1 h. Cell lysates
were prepared and immunoprecipitated using anti-mouse MHC II antibody (1:50;
PharMingen), and then subjected to Western blot using anti-human Aβ antibody (BAM10, 1:1,500; Sigma) (Tan, 2000).

2.3.2 Microscopic analysis of Fluorescence CY3-Aβ
14

Microglial phagocytosis of fibrillar Aβ peptides was carried out similarly to previously
described protocols (Kitamura Y., 2003; Chung, 1997; Webster, 2001; Wyss-Coray,
2003). Microglial cells were cultured in 6-well tissue-culture plates with glass inserts
(for fluorescence microscopy) at 5 x 105/well in the presence or absence of Cy3conjugated Aβ1-42 (3 µM) with agonist anti-CD40 antibody (2.5 µg/mL) or isotypematched IgG (2.5 µg/mL; control) in the presence or absence of lovastatin (10 µM). In
parallel dishes, microglial cells were incubated with Cy3-conjugated Aβ1-42 under the
same treatment conditions above except they were incubated at 4oC to control for nonspecifically cellular association of Cy3-Aβ1-42. Microglial cells were then rinsed 3 times
in Aβ1-42-free complete medium and the media was exchanged with fresh Aβ1-42 free
complete medium for 10 min both to allow for removal of non-incorporated Cy3-Aβ1-42
and to promote concentration of the Cy3-Aβ1-42 peptide into phagosomes. This medium
was withdrawn and microglial cell were rinsed 3 times with ice-cold PBS. For
fluorescence microscopy, microglial cells on glass coverslips were then fixed for 10 min
at 4oC with 4% (w/v) paraformaldehyde (PFA) diluted in PBS. After 3 times of
successive rinses in Tris-buffered saline (TBS), microglia nuclei were detected by
incubation with DAPI for 10 min. and finally mounted with fluorescence mounting media
containing SlowFade anti-fading reagent (Molecular Probes, Eugene, OR) and then
viewed under an Olympus IX71/IX51 fluorescence microscope equipped with a digital
camera system to allow for digital capture of images.

2.3.3 Immunoprecipitation/Immunoblot analysis of Microglial phagocytosis of Aβ
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For detection of cell-associated Aβ, in the presence of pre-aggregated Aβ1-42 (3 µM), in
parallel, primary microglial cells were plated in 6-well tissue culture plates at 5 x 105
cells/well and treated with the same treated conditions described above. Immunoblotting
was carried out with the monoclonal anti-Aβ antibody (BAM-10, 1:1,000 dilution;
Sigma) followed by an anti-mouse IgG-HRP as a tracer. Blots were developed using the
Immun-Star chemiluminescence substrate. The membranes were stripped and then reprobed with a reference anti-mouse actin monoclonal antibody, which allows for
quantification of the band density ratio of Aβ to actin by densitometric analysis.

2.4 Analysis of cytokines by ELISA
As described in previous studies (Tan, 1999), cell culture media were collected for
measurement of cytokines by commercial cytokine ELISA kits (R&D Systems). Cell-free
supernatants were collected and stored at –70°C until analysis. DuoSet™ enzyme-linked
immunoabsorbance assay (ELISA) kits (including TNF-α, IL-1β, IL-6, IL-2 and IFN-γ)
were obtained from R&D Systems (Minneapolis, MN). Cytokines levels in the
supernatants were examined using the respective cytokine ELISA in strict accordance
with the manufacturer's protocols. Cell lysates were also prepared and the Bio-Rad
(Hercules, CA) protein assay was performed to measure total cellular protein from each
of the cell groups. Data are represented as pg/mg total cellular protein for each cytokine.

2.5 Antigen presentation assay
We intraperitoneally immunized C57BL/6 mice at 4 weeks of age with a single dose of
Aβ1-42 or vehicle control (phosphate-buffered saline, PBS) emulsified 1:1 (v/v) in
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complete Freund’s adjuvant. Seven to ten days later, these mice were sacrificed, their
spleens were isolated and homogenized individually in 10 mL of complete medium (Tan,
2000), centrifuged at 5,000 x g, resuspended in 3 mL of RBC lysis (Gentra Systems,
Minneapolis MN), and allowed to stand on ice for 10 min. Seven milliliters of complete
medium was then added to spleen homogenates, the mixture was centrifuged again at
5,000 x g, the supernatants were removed, and the resulting splenocytes were
resuspended in 10 mL of complete medium. CD4+ T-cells were isolated from these
splenocytes as previously described (Tan, 2000) and distributed at a concentration of 1 x
106 cells/well in 24-well plates and co-cultured with Aβ1-42 pre-treated microglial cells at
a concentration of 1 x 105/well in 1 mL of media. Microglial cells had been pre-treated
with Aβ1-42 either in the presence or the absence of CD40L protein for 6 h prior to coculture (Tan, 2002). The resulting co-cultured supernatants were collected for analysis of
cytokines. IFN-γ, IL-2, TNF-α and IL-6 were measured by ELISA as previously
reported (Tan, 2000,2002). Total cellular proteins of each sample were quantified using
the Bio-Rad protein assay, allowing results to be expressed as pg of each cytokine/mg of
total cellular protein.

2.6 CD40 detection in microglial cells
2.6.1 CD40 mRNA detection by Reverse transcriptase-PCR analysis (RT-PCR)
Primary cultured microglial cells were plated at 5 x 105 cells/well in 6-well tissue-culture
plates (Costar, Cambridge, MA) and stimulated for 3 h with IFN-γ (100 U/mL) in the
presence or absence of lovastatin (10 µM). Total RNA was isolated from microglia cell
cultures using Trizol reagent (Invitrogen, Carlsbad, California) as recommended in the
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manufacturer's protocol. RNA concentration was measured by spectrophotometry at
260 nm. RT-PCR was performed as described previously (Tan, 1999a). Briefly, cDNA
was prepared by mixing 1 µg of total RNA from each treatment with an oligo (dT) primer
and the MMLV reverse transcriptase (Invitrogen); the reaction mix was incubated in a
37°C water-bath for 50 min before heat inactivation of the mix by increasing the
temperature to 70°C for 10 min. This cDNA reaction mixture (20 µL) was diluted with
180 µl of DNAase/RNAase-free water and 10 µL of the cDNA solution was used for
gene specific PCR. The PCR primers used were CD40 sense: 5’-CTG CCC AGT CGG
CTT CTT CTC- 3’ and antisense: 5’ -CCT GTG TGA CAG GCT GAC AC- 3’
oligonucleotides were designed to produce the partial 374 bp mouse CD40 cDNA
[37](Tone,, 2000); actin sense: 5' -CAG AGG CTC CCC TAA ATC CC- 3' and actin
antisense: 5' -CAC ACT GAG TAC TTG CGC TC- 3', which yields the 702 bp actin
cDNA fragment. Actin was amplified from all samples as a housekeeping gene to
normalize expression. A control (no template) was included for each primer set. PCR
was performed with each cycle consisting of 94°C for 1 min, 55°C for 2 min, and 72°C
for 2 min, followed by a final extension step at 72°C for 10 min. PCR cycle numbers
were kept low to perform semi-quantitative PCR (actin, 18 cycles; CD40 20 cycles).
PCR products were resolved on 1.2% ethidium bromide-stained agarose gels, and
visualized by ultraviolet transillumination.

2.6.2 Microglial cell surface CD40 protein detection by flow cytometric analysis
For flow cytometric analysis of microglial CD40 expression, primary cultured microglial
cells were plated in 6-well tissue culture plates at 5 x 105 cells/well and incubated with
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IFN-γ (100 U/mL) in the presence or absence of lovastatin (10 µM). Twelve hours after
incubation, microglial cells were washed with flow buffer [PBS containing 0.1% (w/v)
sodium azide and 2% (v/v) FCS] and re-suspended in 250 µl of ice-cold flow buffer for
fluorescence activated cell sorting (FACS) analysis, according to methods described
previously (Tan, 1999c). Briefly, cells were pre-incubated with anti-mouse CD16/CD32
monoclonal antibody (clone 2.4G2, PharMingen) for 10 min at 4°C to block non-specific
binding to Fc receptors. Cells were then spun down at 5,000g washed 3 times with flow
buffer and then incubated with hamster anti-mouse CD40-FITC or isotype control
antibody-FITC (1:100 dilution; PharMingen, Los Angeles, CA) in flow buffer. After 30
min incubation at room temperature, cells were washed twice with flow buffer, resuspended in 250 µL of flow buffer and analyzed by a FACScanTM instrument (Becton
Dickinson, Franklin Lanes, NJ). A minimum of 10,000 cells were accepted for FACS
analysis. Cells were gated based on morphological characteristics such that apoptotic and
necrotic cells were not accepted for FACS analysis using CellQuestTM software (Beckton
Dickinson). Percentages of positive cells (CD40-expressing) were calculated as follows:
for each treatment, the mean fluorescence value for the isotype-matched control antibody
was subtracted from the mean fluorescence value for the CD40-specific antibody.

2.6.3 CD40 protein detection by western blot
For western immunoblotting analysis of microglial CD40 expression, following parallel
treatment, cell lysates were prepared in an ice-cold lysis buffer (20 mM Tris, pH
7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM glycerolphosphate, 1 mM Na3VO4, 1 µg/ml leupeptin, and 1 mM
19

PMSF) and protein concentration was determined by the Bio-Rad protein assay as
previously described (Tan, 2000). An aliquot corresponding to 50 µg of total protein of
each sample was separated by SDS-PAGE and transferred electrophoretically to
immunoblotting PVDF membranes. Nonspecific antibody binding was blocked with 5%
nonfat dry milk for 1 h at room temperature in Tris-buffered saline (20 mM Tris and
500 mM NaCl, pH 7.5). Subsequently, these membranes were first hybridized with the
rabbit anti-CD40 antibody (1:1,500 dilution; StressGen, Victoria, Canada) for 2 h and
then washed 3 times in TBS and immunoblotting was by an anti-rabbit HRP-conjugated
IgG secondary antibody as a tracer. The luminol reagent was used to develop the blots.
To demonstrate equal loading the same-membranes were then stripped with βmercaptoethanol stripping solution (62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 100 mM βmercaptoethanol), and finally re-probed with mouse monoclonal antibody to actin.

2.7 Immunoblot analysis of the JAK/STAT1 signaling pathway
Murine primary culture microglial cells were plated in 6-well tissue culture plates at a
density of 5 x 105 cells per well and incubated with IFN-γ (100 U/mL) in the presence or
absence of a dose range of lovastatin (2.5, 5.0, 10.0 and 20.0 µM) for 30 min.
Immediately after culturing, microglial cells were washed in ice-cold PBS three times
and lysed in an ice-cold lysis buffer. After incubation for 30 min on ice, samples were
centrifuged at high speed for 15 min, and supernatants were collected. Total protein
content was estimated using the Bio-Rad protein assay. For phosphorylation of JAK1
and JAK2, membranes were first hybridized with phospho-specific Tyr1022/1023 JAK1
or Tyr1007/1008 JAK2 antibody and then stripped and finally analyzed by total JAK1 or
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JAK2 antibody. For STAT1 and MAPK p42/44 phosphorylation, membranes where first
hybridized with a phospho-specific p44/42 MAPK antibody, stripped with βmercaptoethanol stripping solution and then re-probed with an antibody that recognizes
total p44/42 MAPK. Other membranes with identical samples were probed with a
phospho-Ser727 STAT1 antibody and stripped with stripping solution and then re-probed
with an antibody that recognizes total STAT1. Alternatively, membranes with identical
samples were probed either with phospho-JAK or STAT1, or with an antibody that
recognizes total JAK or STAT1. Immunoblotting was performed with a primary
antibody followed by an anti-rabbit HRP-conjugated IgG secondary antibody as a tracer.
After washing in TBS the membranes were incubated in the luminol reagent and exposed
to film.

2.8 Statistical analysis.
Data are presented as mean +/- SD. All statistics were analyzed using a one-way
multiple-range analysis of variance test (ANOVA) for multiple comparisons. A value of
p < 0.05 was considered significant.
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CHAPTER THREE

CD45 ISOFORM RB AS A MOLECULAR TARGET TO OPPOSE LPS-INDUCED
MICROGLIAL ACTIVATION
3.1 Introduction
CD45 is a protein tyrosine phosphatase that is expressed on all nucleated
hematopoietic cells and plays an important role in regulating immune responses. By
dephosphorylating Src-family kinases, CD45 promotes antigen-specific B- and T-cell
responses (Penninger, 2001; Thomas, 1999). CD45 plays an additional role in regulating
selectin expression (Stibenz, 1996; Wroblewski, 1997) and integrin function (Roach,
1997; Shenoi, 1999). Recently, CD45 has also been shown to negatively regulate
cytokine receptor mediated signaling via JAK-family kinases, thus revealing a role for
CD45 in multiple hematopoietic lineages (Irie-Sasaki, 2001). Multiple isoforms of CD45
are generated by alternative splicing of exons 4, 5 and 6 (also known as A, B and C) that
encode part of the extracellular region of the molecule. However, the functional roles of
each of the CD45 isoforms on T-cells as well as on other nucleated hematopoietic cells
remains unclear ( Bottomly, 1989; Davies, 1999; Trowbridge, 1994).
Similar to other cells of hematopoietic lineage, resting microglia have been shown
to express CD45 at low to moderate levels, and CD45 expression markedly increases
following their activation (Carson, 1998; Sedgwick, 1991). In addition, it has been
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demonstrated that microglia located in the frontal cortex and hippocampus of normal
aging individuals express CD45 and this expression level is markedly increased in
Alzheimer’s disease patients (Masliah, 1991). Our previous studies have shown that
cross-linking CD45 with an agonistic anti-CD45 antibody markedly inhibits CD40Linduced activity of the Src-family kinases Lck and Lyn. Co-treatment of microglia with
CD40L and agonistic anti-CD45 antibody results in significant inhibition of microglial
TNF-α production via inhibiting p44/42 MAPK activity, a downstream signaling event
resulting from Src-family kinase activation (Tan, 2000). These findings suggest that
stimulation of the CD45 signaling pathway may be directly applicable to suppression of
microgliosis associated with neurodegenerative disorders. In order to address which
CD45 isoform may modulate microglial activation, first we characterized the CD45
isoform profile on resting and activated microglia. Next we determined, in vitro, the
functionality of agonist isoform-specific antibodies to mitigate LPS-induced microglial
activation. Finally, we analyzed the therapeutic potential of a CD45RB specific antibody
in an in vivo model of microgliosis.
Primary murine microglial cells were obtained and cultured as described in our
previous studies (Tan, 1999). Microglial CD45 isoform expression was assessed by
fluorescence activated cell sorting (FACS) analysis. Briefly, cultured microglial cells
were plated in six well-tissue culture plates (Nunclon TM) at 2 x 105 cells/well and
incubated in the presence or absence of LPS. Twenty-four hours after incubation,
microglial cells (approximately 1 x 106 cells) were re-suspended in 250 µl of ice-cold
PBS for FACS analysis using CD45 isoform specific monoclonal antibodies (purified rat
anti-mouse pan-CD45, purified rat anti-mouse CD45RB and purified IgG2b control
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antibodies, FITC-conjugated rat anti-mouse pan-CD45, FITC-conjugated rat anti-mouse
CD45RA, FITC-conjugated rat anti-mouse CD45RB, FITC-conjugated rat anti-mouse
CD45RC and FITC-conjugated rat IgG2b control antibodies) purchased from
PharMingen (San Diego, CA). A minimum of 10,000 cells were accepted for FACS
analysis, being gated based on morphological characteristics such that apoptotic and
necrotic cells were not accepted. Percentages of positive (CD45 expressing) cells were
calculated by substracting the mean fluorescence value for the isotype-matched control
antibody was subtracted from the mean fluorescence value for the CD45 isoform-specific
antibody for each treatment. It should be noted that, because microglia can express more
than one CD45 isoform at once, this method of FACS analysis only permits an
approximate comparison of CD45 isoform expression levels in terms of fluorescence
brightness and does not allow for strict quantitative comparison (i.e. each of the CD45
isoforms will not necessarily sum to that of the pan-CD45).

3.2 Results
3.2.1 CD45RB is the most prevalent CD45 isoform expressed by either resting or
activated microglia
To examine functionality of CD45 isoforms we first evaluated whether crosslinking with CD45 isoform specific antibodies (anti-CD45RA, anti-CD45RB, or antiCD45RC) could result in an agonistic (i.e., stimulatory) effect. As stimulation of CD45
promotes the receptor’s tyrosine phosphatase activity, we measured free inorganic
intracellular phosphate as an activation readout as previously described (Tan, 2000).
Briefly, we utilized various CD45 isoform specific antibodies to immunoprecipitate their
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respective targets from microglial cell lysates. After addition of a phospho-src peptide,
we then measured the amount of free inorganic phosphate released by the Biomol Green
Reagent. All the antibodies tested were effective in stimulating tyrosine phosphatase
activity. The pan-CD45 antibody had a PTP activity (nmol/min)/(OD/mm2) of 0.088
compared to 0.021, 0.031, and 0.017 for anti-CD45RA, RB and RC respectively, whereas
PTP activity was undetectable in the IgG isotype antibody control group.

3.3.2 Ligation of microglial CD45RB antagonizes LPS induced microglial
activation in vitro.
Having established the agonist activity of the various CD45 antibodies, we pretreated microglia with each of the CD45 antibodies, then challenged them with LPS and
examined TNF-α production as a marker of their activation. Briefly, microglial cells
were plated in 24-well tissue-culture plates (Costar, Cambridge, MA) at 5 x 104 cells per
well and stimulated for 18 h with LPS (10 ng/ml; Sigma) in the presence or absence of 2
h pre-treatment with isoform specific CD45 antibodies (each at a 1:200 dilution). Cellfree supernatants were collected and assayed for TNF-α using an ELISA kit (Biosource
International) in strict accordance with the manufacturer’s instructions. Total protein
content of the cell lysate was estimated using the Bio-Rad protein assay kit (Bio-Rad,
Hercules, CA). Thus, TNF-α levels were normalized to total cellular protein and
reported as such.

3.3.3 Ligation of microglial CD45RB antagonizes LPS induced microglial
activation in vivo.
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We further wished to evaluate the possibility that CD45RB might be a negative
regulator of microglial activation in vivo by administering a CD45RB isoform specific
agonistic antibody to mice challenged with LPS. As we required an “industrial” quantity
of antibody for these in vivo experiments, we first obtained a hybridoma cell line
(American Type Culture Collection, Manassas, VA), and subsequently cultured these
cells and purified anti-CD45RB antibody (clone MG23G2) as previously described
(Basadonna, 1998; Birkeland, 1988). Nineteen BALB/C mice were purchased from
Jackson Laboratories (Bar Harbor, ME). Following a two-week acclimation, mice were
divided into the following groups: group 1 (n = 5) received 100 µg of LPS [in 100 µL of
phosphate buffered saline (PBS)] via an intraperitoneal (i.p.) injection route; group 2
(n=4) received a set of i.p. pre-injections with MG23G2 (30 µg per mouse in 100 µL of
volume injected) once a day for three days before the LPS challenge described above;
group 3 (n=7) received PBS vehicle alone (100 µL); lastly, group 4 (n=3) received only
the set of pre-injections with MG23G2. All of the mice were sacrificed 18 hours after the
last injection by transcardial perfusion with PBS under isofluorane anesthesia.
Immunohistochemical detection of CD45 in the brain is widely utilized as a
microglial specific marker. However, detailed examination of which CD45 isoforms are
expressed by microglia, the levels at which they are expressed, and their function(s), is
lacking. Utilizing FACS analysis, we demonstrate that the CD45RB isoform constitutes
approximately 80% of total CD45 expression level on resting microglia (Figure 1). To
characterize the CD45 isoform expression profile in activated microglia, we then
employed the potent microglial activator, LPS. Microglial cells were stimulated with

26

Figure 1.

A. FACS analysis of CD45 isoforms expressed on
resting cultured microglial cells. B. Pooled results show a
predominant expression of isoform CD45RB (85% of total CD45)
n = 3 for each isoform examined.
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LPS (10 ng/ml) for 18 hours, and FACS analysis demonstrates that the CD45 isoform
profile is similar to the resting state (with CD45 isoform RB constituting approximately
80% of the total isoforms expressed), although total CD45 expression increased
following LPS treatment (data not shown).
To characterize the function of microglial CD45 isoforms in the context of
activation, we challenged microglia with an LPS stimulus in the presence of each CD45
isoform-specific agonist antibody. Effects on microglial TNF-α production are reported
but IL-1β was also measured (data not shown) and found to replicate the trends shown
for TNF-α release. As expected, the pan-CD45 isoform antibody (Figure 2, column 3)
most potently suppressed LPS induced TNF-α production (80% inhibition). However, of
the three CD45 isoform specific antibodies used, only anti-CD45RB was able to
dramatically antagonize LPS-induced microglial activation, as evidenced by a 70-75%
reduction of TNF-α (Figure 2).
These data suggest that targeting CD45RB on microglia may offer an effective
and more specific approach to suppressing activation versus total CD45. To examine this
hypothesis in vivo, we evaluated whether mice prophylactically treated with the CD45RB
isoform specific antibody, MG23G2, would benefit in terms of mitigating the
microgliosis normally associated with i.p. LPS challenge. Data show that brain
homogenates from LPS injected mice that received pretreatment with MG23G2 express
significantly less TNF-α compared to mice that did not receive the pretreatment (Figure
3).
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Figure 2.
CD45 isoform RB abrogates LPS-induced TNF-α
production by microglia in vitro. The graph represents a summary
of TNF-α production by ELISA (mean TNF-α pg/mg of total
protein +/- SEM, n=6 for each condition presented). A significance
between-groups difference (p<0.05) was foundby Studentʼs t-test.
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Figure 3.
Brain TNF-α levels in response to LPS challenge
are attenuated by CD45RB antibody pretreatment. The graph
shows TNF-α production as measured by ELISA (mean TNF-α
pg/mg of total protein +/-SEM). Statistical analysis revealed
significance suppression of TNF-α levels in brain homogenates
of mice pretreated with CD45RB antibody MG23G2 compared
to mice injected with LPS only (by Studentʼs t-test, p<0.05).
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3.4

Discussion
Chronic microglial activation has been implicated as a pathogenic factor in a

variety of neurodegenerative diseases such as multiple sclerosis, AIDS dementia, and
Alzheimer’s disease, raising the possibility that therapeutic strategies aimed at opposing
microglial activation may be beneficial in treating such diseases. However, current
attempts at reducing neuroinflammation mediated via chronic microglial activation have
only been partially efficacious (Rich, 1995), possibly because of the fact that such
strategies are better characterized as general inhibitors of inflammation than they are
specific inhibitors of microglial-associated inflammation. In this study, we focused on
characterizing various isoforms of a microglia surface receptor target, CD45, which we
have previously shown is able to antagonize microglia activation (Tan, 2000a,b).
CD45 isoforms have been described on other cell lineages but this is the first time, to our
knowledge, that they have been characterized on microglia cells. We report herein that
CD45RB is the principle isoform of CD45 on murine microglia, either when resting or
following LPS activation. This latter observation is interesting, as it suggests that unlike
T-cells, CD45 isoform switching does not occur following microglial activation. We
further demonstrate that activation of the CD45RB isoform with an isoform specific
antibody is able to potently oppose LPS induced microglial activation in vitro. Finally,
we show in vivo that an agonistic anti-CD45RB antibody is able to attenuate CNS
inflammation induced by i.p. injection of LPS. Specifically, we find that a prophylactic
treatment regimen with anti-CD45RB antibody is able to mitigate LPS induced TNF-α
protein levels in the brain. As microglia are the only CNS cell population that expresses
CD45, it is reasonable to assume that this antibody is exerting its effect on microglia.
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Antibodies against different CD45 isoforms or different epitopes of the same isoform can
elicit different biological effects, and only some have been shown to prolong allograft
survival (Fabre, 1977; Gao, 1999; Goldberg, 1995; Lazarovits, 1996; Rothstein, 2001).
The anti-CD45RB antibody we employed (MG23G2) has been shown to promote the
establishment of allografts and xenografts (Basadonna, 1998; Lazarovits, 1996). This
result is consistent with the idea that MG23G2 opposes immune cell activation not only
in the CNS as we report, but also in the periphery.
Taken together, these data show that stimulation of the CD45 pathway,
specifically the CD45RB isoform, negatively controls microglial activation induced by
proinflammatory stimulation. A suggestion that arises from these results is that
pharmacotherapeutics that specifically stimulate CD45RB may be beneficial for
mitigating microgliosis associated with neurodegenerative diseases.
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CHAPTER FOUR
LOVASTATIN MODULATION OF MICROGLIAL ACTIVATION VIA
SUPPRESSION OF CD40 AND ITS SIGNALING PATHWAY

4.1 Introduction
Statins are effective lipid-lowering agents that inhibit the rate-limiting enzyme of
cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMGCoA). Interestingly, statins have shown clinical efficacy not only in the treatment of
arteriosclerosis and hypercholesterolemia (Shepherd, 1995; Kuivenhoven, 1998;
Garlichs, 2001a,b; Aronow, 2003; Semb, 2003) but also in the treatment of
neurodegenerative diseases like Alzheimer’s Disease (AD) (Wolozin, 2000; Simons,
2002; Kirsch , 2003; Zamrini , 2004). However, a number of studies have shown that
the efficacy of certain statins appear to be dissociated from effects on HMG-CoA
inhibition suggesting that statins display pleiotrophic effects outside of their lipidlowering properties (Lefer, 2001; Marz , 2003). In fact, reports of the effects of statins on
vascular-derived cells suggest that they suppress CD40 expression and subsequent
inflammatory processes ( Schonbeck, 2002; Wagner, 2002; Mulhaupt, 2003).
CD40 is a 50 kDa type I phosphoprotein that is a member of the TNF-receptor
superfamily. CD40 is expressed by a wide variety of cells (Schönbeck, 2001). The
ligand for CD40 (CD154) is expressed mainly on activated CD4+ T-cells, although other
cells such as vascular endothelial cells, smooth muscle cells, macrophages, and astrocytes
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have the capacity to express CD154. Upon ligation of CD40, numerous cell-type
dependent signaling pathways are activated, leading to changes in gene expression and
function. These changes include NF-kB, mitogen-activated protein (MAP) kinases,
TNFR-associated factor proteins, PI3K, and the JAK/STAT pathway (van Kooten,
2000a,b). Ligation of CD40 on microglial cells leads to the production of TNF-α and
other unidentified neurotoxins (Aloisi, 1999; Fischer, 2001; D’Aversa, 2002). Thus,
signaling through CD40 on microglial cells induces a number of soluble mediators that
have important functional roles in the central nervous system (CNS).
In the normal brain, microglia display a quiescent phenotype including low CD40
expression (Tan, 1999a). However upon insult to the brain, microglia become highly
activated, altering their phagocytic and antigen presentation functions (Townsend,
submitted 2004) as well as the production of cytokines (Aloisi, 2001). Mounting
evidence implicates microglial CD40 as contributing to the initiation and/or progression
of several neurodegenerative diseases including: HIV-1-associated dementia (D'Aversa,
2002), multiple sclerosis (MS) (Grewal, 1996; Laman, 1998a; Becher, 2001; Nath, 2004),
and AD (Togo, 2000; O'Keefe, 2002; Calingasan, 2002). In fact, blocking CD40–CD154
interactions by a neutralizing antibody strategy prevents murine experimental
autoimmune encephalomyelitis (EAE) disease activity (Gerritse, 1996; Laman, 1998b;
Boon, 2001; Howard, 2003), as well as AD-like pathology in mouse models of the
disease (Tan, 2002).
Given the epidemiological data supporting the use of statins in AD and the recent
work showing that statins oppose CD40 expression in vascular derived cells, we now
examine whether statins (specifically lovastatin – also referred to as mevinolin) could
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oppose microglial CD40 expression and its signaling pathway following IFN-γ challenge.
Furthermore, we examine whether lovastatin influences microglial phagocytic function
and/or pro-inflammatory cytokine production after CD40 ligation.

4.2 Results
4.2.1 Lovastatin inhibits IFN-γ and Aβ peptide induced CD40 expression in
microglia
Although previous studies have shown that CD40 expression is constitutively
expressed at low levels in microglial cells; CD40 expression is dramatically induced in
response to IFN-γ or Aβ peptide challenge (Nguyen, 1998; Tan, 1999a,b). In order to
examine lovastatin regulation of CD40 expression in microglial cells, cultured mouse
microglial cells were treated with IFN-γ (100 U/mL) for 3 h and mRNAs for CD40 were
analyzed by semi-quantitative RT-PCR. Consistent with our previous data and the data
of others, IFN-γ challenge produced a robust increase in CD40 mRNA expression (Figure
4). Lovastatin treatment (2.5 to 20 µM) did not affect constitutive CD40 expression
(Figure 4, lane 5 from left), but the 10 µM dose markedly inhibited IFN-γ induced CD40
expression (Figure 4, lane 10 compared to lane 7 from left). Interestingly, under the same
treatment conditions IFN-γ induced CD40 mRNA expression was not affected by either
the MAPK inhibitors (PD98059 or SB203580) for p42/44 MAPK or p38 MAPK
respectively (data not shown). To examine whether lovastatin’s inhibition of CD40
mRNA led to a similar reduction in protein expression, western immunoblot and FACS
analyses were performed on primary mouse microglial cells and the N9 microglial cells
line (data not shown) cultured in the presence of IFN-γ (100 U/mL) for 12 h. IFN-γ
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Figure 4.
Lovastatin inhibits microglial CD40 expression
induced by IFN-γ. Mouse primary microglial cells were
cultured in six-well tissue-culture plates (500,000/well) and
treated with IFN-γ (100 U/ml) in the presence or absence
of lovastatin (Lova) at the indicated doses or treated with vehicle
(1% DMSO, control) for 3 hr. Total RNA was prepared from
these cells and subjected to RT-PCR for analysis of microglial
CD40 mRNA expression.
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produced a substantial increase in CD40 expression as measured by western
immunoblotting (Figure 5a) and quantitative corrected mean fluorescence units (Figure
5b). In both cases, lovastatin co-treatment mitigated the inducible increase in CD40
protein expression in primary cultured microglial cells (Figure 5a,b). Taken together,
these findings demonstrate that lovastatin opposes IFN-γ induced CD40 expression on
primary cultured microglial cells.

4.2.2 Lovastatin inhibits JAK/STAT signaling pathway induced by IFN-γ in
microglia
As previously mentioned, IFN-γ is a potent inducer of microglial CD40
expression and the signal transduction pathway involved in this induction has been
described by many to involve elements of the JAK/STAT signaling pathway.
Interestingly, many of the factors (cytokines, neurotrophins, neuropeptides) that inhibit
IFN-γ induced microglial CD40 expression do so by modification of the JAK/STAT
pathway Nguyen, 2000a,b; Wei, 1999; Delgado, 2003; Kim, 2002). Therefore, we
examine the effects of lovastatin on the JAK/STAT signaling pathway in culture mouse
microglial cells. Mouse microglial cells were treated with IFN-γ for 30 min in the
presence or absence of a dose range of lovastatin (0-20 µM). Western immunoblotting
analysis revealed that lovastatin markedly mitigated JAK1 Tyr1022/1023 and JAK2
Tyr1007/1008 phosphorylation at 10 µM dose (Figure 6a, panel 1 to 4). However, the
phosphorylation of JAK1 and JAK2 was only slightly inhibited by lovastatin at 5 µM.
Furthermore, it is well known that during IFN-γ interaction with its heterodimer type II
cytokine receptor, the JAKs are directly activated leading to STAT1 phosphorylation
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Figure 5.
Lovastatin inhibits microglial CD40 expression induced by
IFN-γ. Mouse primary microglial cells were cultured in six-well tissue
culture plates (500,000/well) and treated with IFN-γ (100 U/ml) in the
presence or absence of lovastatin (Lova) at the indicated doses or treated
with vehicle (1% DMSO; control) for 12 h. A. Cell lysates were prepared
from these cells and subjected to Western immunoblotting for analysis
of microglial CD40 expression. B. FACS analysis of CD40 expression.
ANOVA and post hoc testing showed significant differences in mean
fluorescence (+/-SD, with n=3 for each condition) between IFN-γ
treatment and IFN-γ treatment in the presence of lovastatin (P<0.001).
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Figure 6.
Lovastatin treatment opposes IFN-γ-induced phosphorylation
of JAK/STAT1 in microglial cells. Primary microglial cells were
seeded in six-well tissue-culture plates (500,000/well) and treated with
IFN-γ (100 U/ml) in the presence or absence of lovastatin (Lova) at the
indicated doses or treated with vehicle (1% DMSO; control) for
30 min. Cell lysates were prepared from these cells and subjected to
Western immunoblotting by using antibodies against phospho-JAK1
(Tyr1022/1023) and JAK2 (Tyr1007/1008) or total JAK1 and JAK2 as
indicated. Results are representative of three independent experiments.
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(Nguyen, 2000a,b; Delgado, 2003). Accordingly, we examined the effects of lovastatin
on STAT1 phosphorylation, in the same dose range mentioned above, on primary
microglial cells treated with IFN-γ for 30 min. Data showed that lovastatin significantly
inhibited Ser727 phosphorylation of the STAT1 protein at 10 µM (Figure 7, panels 1 and
2); consistent with the effects on JAK phosphorylation, 5 µM of lovastatin was less
effective. The MAPK pathway has been reported to mediate full transcription activation
of STAT-1 by the phosphorylation of Ser727 (Goh, 1999; Dalpke, 2003). We therefore
investigated whether p42/44 MAPK phosphorylation status reflected that of STAT-1.
Data revealed that there was no change in p42/44 MAPK phosphorylation status in
microglial cells treated with IFN-γ for 30 min in the absence or presence of lovastatin
(Figure 7, panel 3 and 4). Taken together these observations suggest that lovastatin
opposes IFN-γ induction of the JAK/STAT pathway in microglial cells without affecting
p42/44 MAPK phosphorylation.

4.2.3 Lovastatin inhibits functional CD40 signaling in microglia
To examine functional consequences of lovastatin treatment on CD40 expression,
we stimulated mouse primary microglial cells with either IFN-γ/agonist anti-CD40
antibody or Aβ1−42 /agonist anti-CD40 antibody in the presence or absence of lovastatin
for 12 h. Supernatants from each treatment condition were examined by ELISA for a
panel of pro-inflammatory molecules that we have previously described as being induced
by microglial CD40 ligation (Tan, 1999a,b,c; 2000). As we expected, ELISA
measurements revealed that either IFN-γ/agonist anti-CD40 antibody or Aβ1−42/agonist
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Figure 7.
Lovastatin treatment opposes IFN-γ -induced phosphorylation
of JAK/STAT1 in microglial cells. The same cell lysates used for the
previous experiment were subjected to Western immunoblotting using
anti-phospho-STAT1 (Ser727) or anti-total STAT1 antibody as indicated.
Similar results were obtained in three separate experiments.
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anti-CD40 antibody induced the secretion of the pro-inflammatory molecules IL-6, IL-1β
and TNF-α, as indicated in Figures 8-10. However, when stimulated in the presence of
lovastatin, all of these pro-inflammatory proteins were significantly reduced (Figures 810). The conical microglia function in the CNS is thought to be phagocytosis, and given
that IFN-γ and CD40 signaling are maturation agents that oppose this phagocytic function
(Aloisi, 2000; Magnus, 2001; Chan, 2001; Re, 2002; Monsonego, 2003a,b), we
examined whether lovastatin co-treatment could rescue microglia phagocytic function.
Primary mouse microglial cultures were exposed to 3 µM of Aβ1−42 (for immunoblotting)
or Cy3-Aβ1-42 (for phagocytosis assay) in the presence or absence of agonist anti-CD40
antibody or agonist anti-CD40 antibody/lovastatin. After 3 h, the amount of
phagocytosed Aβ peptide was determined by both qualitative immunofluorescence
studies (Figure 11) and with quantitative immunoblotting experiments (Figure 12). As
shown in Figure 11, agonist anti-CD40 antibody pre-treatment decreased microglia
phagocytic function compared to controls (panel 1 versus 3 or 4), while lovastatin
treatment alone did not differ from that of control (panel 1 versus 2). Interestingly, the
presence of lovastatin rescued microglial phagocytosis of Aβ following agonist antiCD40 antibody treatment (Figure 11, panel 4 versus 3). In a parallel experiment, we
further showed that the presences of lovastatin resulted in a significant attenuation of
impaired microglial phagocytosis of Aβ induced by agonist anti-CD40 antibody, as
evidenced by increased band density ratio of Aβ to actin using western immunoblotting
(Figure 12).
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Figure 8.
Lovastatin opposes the effects of IFN-γ /CD40 cross-linking or
Aβ /CD40 cross-linking on TNF-α production in microglial cells.
Cytokine ELISA from cell lysates of mouse primary microglial cells
cotreated with either IFN-γ (IFN-γ;100 U/ml)/agonist anti-CD40 antibody
(CD40 cross-linking; 2 µg/ml) or Aβ 1–42 (3 µM)/agonist anti-CD40
antibody (CD40 cross-linking; 2 µg/ml) in the presence or absence
of lovastatin (Lova 10 µM) or treated with vehicle (1% DMSO; control)
for 24 h. Data represent as mean picograms of each cytokine per
milligram of total cellular protein (+/-S.D).
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Figure 9.
Lovastatin opposes the effects of IFN-γ /CD40 cross-linking or
Aβ /CD40 cross-linking on IL-1β production in microglial cells.
Cytokine ELISA from cell lysates of mouse primary microglial cells
cotreated with either IFN-γ (IFN-γ;100 U/ml)/agonist anti-CD40 antibody
(CD40 cross-linking; 2 µg/ml) or Aβ 1–42 (3 µM)/agonist anti-CD40
antibody (CD40 cross-linking; 2 µg/ml) in the presence or absence
of lovastatin (Lova 10 µM) or treated with vehicle (1% DMSO; control)
for 24 h. Data represent as mean picograms of each cytokine per
milligram of total cellular protein (+/-S.D.).
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Figure 10.
Lovastatin opposes the effects of IFN-γ /CD40 cross-linking or
Aβ /CD40 cross-linking on IL-6 production in microglial cells.
Cytokine ELISA from cell lysates of mouse primary microglial cells
cotreated with either IFN-γ (IFN-γ;100 U/ml)/agonist anti-CD40 antibody
(CD40 cross-linking; 2 µg/ml) or Aβ 1–42 (3 µM)/agonist anti-CD40
antibody (CD40 cross-linking; 2 µg/ml) in the presence or absence
of lovastatin (Lova 10 µM) or treated with vehicle (1% DMSO; control)
for 24 h. Data represent as mean picograms of each cytokine per
milligram of total cellular protein (+/-S.D.).
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Figure 11.
Lovastatin treatment attenuates CD40 cross-linking impairment
of microglial phagocytosis of Aβ. Immunofluorescence microscopy of
mouse primary microglial cells were treated with 3 µM Cy3-Aβ1–42
in the absence (control) or presence of either lovastatin (10 µM) or
agonist anti-CD40 antibody (CD40 cross-linking), or both lovastatin
and CD40 cross-linking (left panel). DAPI staining reveals the presence
of microglia cells as identified by their nuclei (right panel).
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A.

B.

Figure 12.
Lovastatin treatment attenuates CD40 cross-linking
impairment of microglial phagocytosis of Aβ. A. Under the same
treatment conditions of the previous experiment, microglial cell
lysates were prepared for Western immunoblotting analysis of
cell-associated Aβ with anti-Aβ antibody. B. Aβ mean band density
ratios to actin SD are shown (n =3 for each condition). ANOVA
revealed significant between-group differences (P <0.01), and
post hoc testing showed significant differences between CD40
cross-linking alone and lovastatin/CD40 crosslinking.
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4.3 DISCUSSION
The present findings demonstrate that statins, namely lovastatin, reduce IFN-γ
induced upregulation of CD40 expression in mouse microglial cells by interfering with
the JAK/STAT pathway. Given that this finding is consistent with the effects of
lovastatin in IFN-γ treated vascular derived cells (Wagner, 2002; Schonbeck, 2002;
Mulhaupt, 2003), the significance of lovastatin blocking IFN-γ induced microglial CD40
expression must be considered in the context of the function of microglial CD40.
Aberrant expression of CD40 by macrophages/microglia, in conjunction with the release
of TNF-α, is directly correlated with pathogenic events occurring in the CNS in the
disease of multiple sclerosis (Wagner, 2002; Schonbeck, 2002; Mulhaupt, 2003). It is
also clear that CD40 expression by microglial cells is pivotal for disease initiation and
progression in the EAE mouse model of MS (Becher, 2001). In AD, activated microglia
are considered to be a major contributor to the local inflammatory responses evidenced
in neuritic plaques. Furthermore the CD40-CD40L dyad is potentiated as seen by the
increased CD40-positive microglia as well as increased CD40L expression on astrocytes
in AD (Calingasan, 2002). Our previous work has shown a correlation between
increased levels of Aβ peptide and enhanced CD40 expression on microglia derived
from the Tg2576 mouse model of AD (Tan et al, 1999a). We have also shown that Aβ
challenge induces microglial CD40 expression, the ligation of which resulted in the
production of microglial derived neurotoxins (Tan, 1999a). In vivo validation of a
pathogenic role for microglial CD40 was shown by the beneficial effects of strategies
(CD40 neutralizing antibodies or CD40L genetic knockouts) involving the blockade of
CD40 signaling in AD mouse models (Tan, 2002).
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In addition to the epidemiological studies suggesting that statin use is associated
with a lower incidence of AD, a number of reports have also shown that lovastatin can
reduce plasma Aβ levels in AD patients (Friedhoff, 2001; Buxbaum, 2002) and the
increased reports of its HMG-CoA independent properties. Our study suggests that one
of lovastatin’s mechanisms of action may be the attenuation of pathogenic microglial
CD40 expression. Two other statins, atorvastatin and cerivastatin, were previously
shown to inhibit CD40 expression in monocytes and macrophages, although the
mechanism of action was not determined (Garlichs, 2001; Youssef, 2002). A review of
the molecular basis of CD40 expression in macrophages/microglia illuminates the critical
role of the JAK/STAT pathway (Benveniste, 2004). In this study, we show that
lovastatin inhibits IFN-γ induced microglial CD40 expression by opposing JAK/STAT
pathway activation. One possible mechanism of lovastatin’s inhibition of the JAK/STAT
pathway is provided by a recent report showing that in macrophages, lovastatin treatment
induced suppressor of cytokine signaling protein (SOCS), which uncoupled IFN-γ from
STAT activation (Huang, 2003). Moreover, constitutive overexpression of the SOCS-1
protein in the murine macrophage cell line RAW264.7, has been shown to inhibit IFN-γ,
but not LPS induced CD40 expression (Wesemann, 2002). The SOCS proteins act as
negative regulators of the JAK/STAT pathway either by binding and inhibiting JAK
tyrosine kinases or by inhibiting binding of STAT factors to the cytoplasmic domains of
the respective receptors (Yasukawa, 2000). Interestingly, in the study by Huang, a 10
µM dose of lovastatin did not induce macrophage SOCS-3 protein expression until 16 h
after treatment. In our study, however, lovastatin at the same dose inhibited not only
JAK/STAT phosphorylation, but also CD40 mRNA within 30 min and 3 h, respectively.
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This suggests that lovastatin’s acute effects on IFN-γ signaling do not involve SOCS-3.
We cannot, however, rule out a role for SOCS-3 induction by lovastatin in abrogation of
IFN-γ induced microglial pro-inflammatory cytokine production or phagocytic function
because of the longer treatment times employed in those assays.
We have previously shown that antagonizing microglial CD40 expression or
CD40 downstream signaling pathways could also block microglial production of proinflammatory mediators (Tan, 2000; 2002). In this study, we have shown that lovastatin
similarly inhibited microglial CD40 ligation induced proinflammatory cytokine
production. This finding is consistent with other reports of lovastatin inhibiting
microglial production of pro-inflammatory mediators (Pahan, 1997; Tringali, 2004; Nath,
2004). Recent studies have shown that lovastatin possesses anti-inflammatory and
immunomodulatory properties, distinct from its action of lowering serum lipid levels.
Contrasting with other lipid lowering strategies, lovastatin has shown clinical efficacy in
the treatment of Alzheimer’s disease (AD) suggesting that lovastatin’s therapeutic effect
in AD may be derived from the modulation of immune/inflammatory processes.
Given the importance of CD40 and CD154 in neurologic diseases and the
contribution of macrophages/microglia to the disease process, we have been particularly
interested in the regulation of CD40 expression in these cells. It has been reported that
IFN-γ is a potent stimulator of microglial CD40 expression (Nguyen, 1998). In addition,
we have previously made the observation that the Alzheimer’s Aβ peptide can synergize
with the IFN-γ signaling pathway to drastically induce microglial CD40 expression and
subsequent neurotoxicity (Tan, 1999a). Based on this finding, we have done extensive
work on the role of microglial CD40 expression in AD pathogenesis (Town, 2001; Tan,
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2002). In AD brain, CD40 expression has been detected in microglia aggregates and colocalized with Aβ-positive senile plaques (Togo, 2000). A recent publication
demonstrated abundant CD154-positive astrocytes in AD brain in close apposition to
reactive microglia and Aβ-positive senile plaques (Calingasan, 2002), suggesting
astrocytes may be the source of CD154 in AD brain.
The role of lovastatin on promoting microglial phagocytic function is of great
interest given that mechanisms that drive the clearance of cerebral β-amyloid underlie the
principle behind many therapeutic strategies for AD. Interestingly, one study has
recently addressed the role of lovastatin on AD-type pathology in the Tg2576 mouse
model (Park, 2003). They found that while a 3-week treatment with lovastatin reduced
plasma cholesterol levels in both male and female Tg2576 mice, it actually enhanced
cerebral Aβ peptide and β-amyloid plaque in the female Tg2576 mice. The authors
suggest that low plasma cholesterol might be a risk factor for AD in females.
Unfortunately, this study does not examine microglial activation status (morphological or
immunophenotypic) or provide any biological index of lovastatin’s CNS accessibility
during the 3 week treatment regimen. These parameters are critical to an assessment of
lovastatin’s, in vivo effects on microglia function or effects on AD pathology. In another
study using the PSAPP mouse model of AD, the CNS permeable cholesterol-lowering
drug BM15.766 was able to reduce cerebral Aβ peptide levels and β-amyloid plaque load
(Refolo, 2001), suggesting that lovastatin’s limited CNS-accessibility might explain the
effects observed by Park, et al.
In summary, we show that lovastatin decreases CD40 expression in cultured
mouse microglial cells. By reducing microglial CD40 expression and signaling, statins
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such as lovastatin may reduce inflammation as well as promote microglial phagocytic
function, features believed to be important in other therapeutic strategies for AD. Our
findings not only provide an additional explanation for the previously unknown non-lipid
effects of lovastatin on microglial cells, but they also suggest their application in AD and
other neuroinflammatory diseases in which microglial CD40 is involved.
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CHAPTER FIVE
CD40 SIGNALING REGULATES INNATE AND ADAPTIVE ACTIVATION OF
MICROGLIA IN RESPONSE TO Aβ

5.1 Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease with primary
neuropathological hallmarks of intracellular neurofibrillary tangles and extracellular
senile plaques comprised primarily of amyloid-β peptide (Aβ). Additionally, the AD
brain is also characterized by marked microglia-mediated immune responses, the role of
which has become potentially important, yet unclear. On the one hand, activated
microglial cells have been implicated in AD pathogenesis by promoting Aβ plaque
formation as well as pro-inflammatory cytokine production (Wegiel, 2000; Wisniewski,
1994); on the other hand, studies have shown that microglial cells are involved in
phagocytic Aβ plaque clearance (Rogers, 2000;2002). Microglial cells, as resident
macrophages of the brain, form the first line of defense against invading pathogens and
provide a key link between the central nervous system (CNS) and the immune system. In
the normal adult brain, microglial cells are relatively quiescent, but in response to CNS
injury, they actively phagocytose cellular debris and dying cells (Kreutzberg, 1996). This
phagocytic uptake of apoptotic cells by microglial cells results in reduced proinflammatory cytokine production and minimizes damage in the inflamed brain (Magnus,
2002).
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In both the clinical syndrome and in animal models of AD, there is increased
activation and recruitment of microglial cells to areas of cerebral amyloidosis, but these
activated microglia fail to clear Aβ deposits in Alzheimer’s mice (Stalder, 1997).
However, the employment of therapeutic strategies that boost microglial phagocytic
activation is able to reduce cerebral Aβ load in mouse models of AD. This is exemplified
by a report showing that transforming growth factor-beta (TGF-β) overexpression
promotes phagocytic clearance of cerebral Aβ (Wyss-Coray, 2001). Similarly, microglial
Fc-receptor mediated removal of Aβ is proposed as one mechanism by which Schenk and
colleagues’ peripheral immunization of the PDAPP mouse model of AD with Aβ1-42
resulted in reduced Aβ plaque burden (Schenk, 1999). Interestingly, macrophage colonystimulating factor (M-CSF) has also been shown to promote microglial phagocytic
removal of Aβ and the osteopetrotic mice, which lack functional M-CSF, develop CNS
fibrillar plaques (Kaku, 2003). Taken together it seems that microglial phagocytic ability
can be mobilized to promote Aβ removal but endogenous mechanisms fail to effectively
initiate this process. We have previously identified that microglial CD40 receptor
(CD40) potentiates Aβ peptide- induced tumor necrosis factor-alpha (TNF-α) production
and subsequent in vivo studies demonstrated that blockage of CD40 signaling [either by
antibody depletion of the ligand for CD40 (CD40L) or crossing with CD40L-/- mice] was
able to reduce cerebral Aβ/β-amyloid load in an AD mouse model (Tan, 1999; 2002).
CD40 is a ~ 45-50 kDa cell surface molecule and a member of the TNF-α/nerve
growth factor receptor superfamily (van Kooten, 2000). A variety of professional and
non-professional antigen presenting cells (APC) express CD40, including dendritic cells,
B cells, monocytes/tissue macrophages and microglial cells (van Kooten, 2000). Its
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cognate ligand, CD40L, is typically found on the surface of activated T lymphocytes, but
it is also expressed in the CNS by astrocytes. Moreover, expression of CD40 and CD40L
has been found in and around Aβ plaques in AD brain (Togo, 2000; Calingasan, 2002).
Effects of CD40 ligation on maturation, activation, and survival of dendritic cells
suggests that CD40-CD40L interaction plays an important role in APC mediated immune
responsiveness (Kikuchi, 2000; McLellan, 2000).
Increasing evidence in AD mouse models suggests that there are multiple forms
of microglial activation, some manifestations of which may act to promote Aβ/β-amyloid
pathology, while other forms may act to remove this pathology. We propose two types of
activated microglial cells in the context of Aβ, specifically, a phagocytic phenotype and
an APC phenotype. Promotion of the phagocytic phenotype would be associated with
anti-inflammatory cytokine production and would inhibit Aβ plaque formation while the
APC phenotype, given the rare presence of T-cells in the AD brain, would essentially
result in unchecked production of APC-associated pro-inflammatory cytokines that
would act to exacerbate AD-like pathology. Given their pleiotrophic presentation once
activated, we suggest that microglial phenotypes are determined in part by their local
brain milieu. Thus, in the context of the evolving Aβ plaques of AD, we hypothesize that
engagement of microglial CD40 represents one mechanism to shift activated microglial
response away from phagocytic and towards antigen presentation, thus rendering these
cells ineffective at Aβ removal. To test this hypothesis, we have employed primary
murine microglial cells to investigate the role of CD40 signaling in phagocytosis, antigen
presentation, and cytokine response of microglial cells to Aβ.
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5.2 Results
5.2.1 The CD40-CD40L interaction retards microglial phagocytosis and clearance
of Aβ 1-42 peptide
Microglial phagocytosis of Aβ has been deemed a principle mechanism governing the
removal of Aβ from the brain parenchyma (Bard, 2000) and the CD40-CD40L
interaction is a critical modulator of immune cell activation. We wished to evaluate
whether CD40 ligation could inhibit microglial uptake of Aβ. Thus, we added “aged”
FITC-tagged Aβ1-42 to primary murine microglial cells for 15 min, 30 min and 60 min in
the absence or presence of anti-Aβ antibody (clone BAM-10 as a positive control),
isotype-control IgG, CD40L or heat-inactivated CD40L. As a control for non-specific
incorporation of Aβ by microglia, microglial cells were incubated at 4oC in parallel cellculture plates under the same treatment conditions described above. Cell supernatants
and lysates were analyzed for extracellular (Figure 13) and cell-associated (Figure 14)
FITC-Aβ using a fluorometer. As shown in Figure 13a,b, data indicate that the CD40CD40L interaction results in decreased microglial uptake of Aβ1-42 peptide. Consistent
with a previous report (Rogers, 2002), treatment with the positive control (antiAβ antibody) markedly increased microglial uptake of Aβ1-42 peptide at 60 min.
It should be noted that there is not always a direct correlation between microglial
phagocytosis and removal of Aβ (Webster, 2000a,b). Therefore, we wished to determine
whether retarded microglial phagocytosis of Aβ following CD40 ligation also produced
decreased removal of the peptide. We treated primary cultured microglial cells with
“aged” Aβ1-42 in the presence of CD40L or heat-inactivated CD40L protein for 6 h.
Microglial culture media were collected and immunoprecipitated with anti-Aβ antibody,
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Figure 13.
The CD40-CD40L interaction retards microglial phagocytosis
of Aβ1-42 peptide over the indicated time points (a) 15 min (b) 30 min and
(c) 60 min. Data are represented as fold of mean fluorescence change
for each sample at 37ºC relative to mean fluorescence change for each sample
at 4ºC with n = 6 for each condition presented. One-way ANOVA
followed by post-hoc comparison showed a significant difference between
control and CD40L treatment (p < 0.001), but no significant difference
between control and denatured CD40L treatment (p > 0.05).
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Figure 14.
The CD40-CD40L interaction retards microglial phagocytosis
of Aβ1-42 peptide. Data are represented as fold of mean fluorescence change
for each sample at 37ºC relative to mean fluorescence change for each sample
at 4ºC with n = 6 for each condition presented. One-way ANOVA
followed by post-hoc comparison showed a significant difference between
control and CD40L treatment (p < 0.001), but no significant difference
between control and denatured CD40L treatment (p > 0.05).
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and data showed that CD40L protein treatment prevented Aβ removal from the culture
media relative to heat-inactivated control (Figure 15a and b). In addition, microglial cells
were extensively washed and lysed for Western blot analysis of Aβ, and densitometry
showed that CD40L treatment resulted in a six-fold reduction in the amount of cellassociated Aβ (Figure 16). Taken together, these data suggest that CD40 ligation retards
the ability of microglial cells to remove “aged” exogenously added human Aβ1-42.

5.2.2 Microglial secreted APC-associated cytokines TNF-α, IL-6 and IL-1β are
significantly increased in the presence of Aβ following CD40L ligation
We have previously shown that ligation of microglial CD40 leads to the synergistic
activation of microglial cells by Aβ, as evidenced by TNF-α release and bystander
neuronal cell injury (Tan, 1999). In addition, it is well known that the CD40-CD40L
interaction is critical for promotion of APC differentiation of monocytes, macrophages
and dendritic cells, as evidenced by production of pro-inflammatory cytokines such as
TNF-α, IL-6, and IL-1 (Kikuchi, 2000). To investigate whether CD40 ligation promotes
microglial APC differentiation in the presence of Aβ1-42 peptide, we examined cytokine
profiles in the supernatants of microglial cells co-treated with CD40L protein and Aβ1-42
peptide for 48 h. Data show that co-treatment of microglia with CD40L protein and Aβ142

peptide synergistically increased microglial production of APC-associated TNF-α, IL-

6 and IL-1β cytokines (Figure 17-19).
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B.

A.

Figure 15.
A. The CD40-CD40L interaction retards microglial clearance
of Aβ1-42 peptide. A. Immunoprecipitation and Western blot showing
Aβ in cultured media of microglial cells treated with “aged” Aβ1-42
(3 μM) in the presence or absence of CD40L protein (2 μg/mL) for 1 h.
B. Band density ratio of Aβ to IgG (mean +/- 1 SD) for panel A with
n = 4 for each condition presented. One-way ANOVA followed by
post-hoc comparison revealed a significant difference between Aβ1-42
treatment and the Aβ1-42/CD40L co-treatment condition (p < 0.001).
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A.

B.

Figure 16.
A. The CD40-CD40L interaction retards microglial clearance
of Aβ1-42 peptide. A. Immunoprecipitation and Western blot showing
Aβ in cultured media of microglial cells treated with “aged” Aβ1-42
(3 μM) in the presence or absence of CD40L protein (2 μg/mL) for 1 h.
B. Band density ratio of Aβ to actin (mean +/- 1 SD) for panel A with
n = 4 for each condition presented. One-way ANOVA followed by
post-hoc comparison revealed a significant difference between Aβ1-42
treatment and the Aβ1-42/CD40L co-treatment condition (p < 0.001).
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Figure 17.
CD40 ligation in the presence of Aβ results in increased
levels of microglial TNF-α production. Murine primary microglial
cells were treated with Aβ1-42 peptide in the presence of CD40L
protein or heat-inactivated CD40L for 48 h. Data are represented
as pg of TNF-α detected by ELISA per mg of total cellular protein
with n = 3 (mean +/- 1 SD). One-way ANOVA followed by post-hoc
comparison revealed a significant difference between Aβ/inact.
CD40L and Aβ/CD40L protein (p < 0.001)

62

Figure 18.
CD40 ligation in the presence of Aβ results in increased
levels of microglial IL-6 production. Murine primary microglial
cells were treated with Aβ1-42 peptide in the presence of CD40L
protein or heat-inactivated CD40L for 48 h. Data are represented
as pg of IL-6 detected by ELISA per mg of total cellular protein
with n = 3 (mean +/- 1 SD). One-way ANOVA followed by post-hoc
comparison revealed a significant difference between Aβ/inact.
CD40L and Aβ/CD40L protein (p < 0.001)
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5.2.3 CD40 signaling-associated Th1, but not Th2, cytokines inhibit microglial
phagocytosis of Aβ 1-42
It is becoming increasingly substantiated that the CD40-CD40L interaction promotes T
helper type 1 (Th1) cell differentiation as evidenced by increased production of proinflammatory cytokines such as TNF-α by the APC and IFN-γ by the Th1 cell (Dong,
2001). In order to examine putative modulation of microglial phagocytosis of Aβ by
CD40 signaling-associated Th1 cytokines, microglial cells (in 24-well tissue-culture
plates, 1 x 105 cells/well) were treated with 300 nM of “aged” FITC-tagged Aβ1-42 in the
presence or absence of recombinant Th1 cytokines (IFN-γ and/or TNF-α) or T helper
type 2 (Th2) cytokines (IL-4 and/or IL-10 as controls for Th1 cytokines). One hour after
treatment, cell culture supernatants were collected and cell lysates were prepared to
measure Aβ by fluorometry. In parallel experiments, microglial cells were treated with 3
µM of “aged” human synthetic Aβ1-42 in the presence or absence of the Th1 or Th2
cytokines mentioned above, and 1 hour after treatment, cell lysates were subjected to
Western analysis using mouse monoclonal antibody clone BAM-10, which specifically
recognizes human Aβ. As consistently shown when analyzing both microglial
conditioned media (Figure 20) and lysates (Figure 21), CD40 signaling-associated Th1
cytokines inhibit whereas Th2 cytokines boost microglial uptake of Aβ1-42.

5.2.4 CD40 ligation promotes formation of microglial MHC II-Aβ peptide complex
Having shown that both CD40 ligation and Th1 cytokines retarded microglial uptake and
clearance of Aβ peptide, we wondered whether CD40L might shift microglial activation
towards an APC phenotype. Major histocompatibility complex II (MHC II) plays a
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Figure 19.
CD40 ligation in the presence of Aβ results in increased
levels of microglial IL-1β production. Murine primary microglial
cells were treated with Aβ1-42 peptide in the presence of CD40L
protein or heat-inactivated CD40L for 48 h. Data are represented
as pg of IL-1β detected by ELISA per mg of total cellular protein
with n = 3 (mean +/- 1 SD). One-way ANOVA followed by post-hoc
comparison revealed a significant difference between Aβ/inact.
CD40L and Aβ/CD40L protein (p < 0.001)
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Figure 20.
TNF-α and IFN-γ cytokines promote whereas IL-4
and IL-10 cytokines inhibit microglial phagocytosis of Aβ.
Murine primary cultured microglial cells were treated with
300 nM of “aged” FITC-tagged Aβ1-42 in the presence or
absence (control) of the recombinant cytokines indicated.
One hour after treatment, cell culture supernatants were
collected for (A), and cell lysates were prepared for (B).
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Figure 21.
TNF-α and IFN-γ cytokines promote whereas IL-4
and IL-10 cytokines inhibit microglial phagocytosis of Aβ.
Microglia were treated with 3 μM of “aged” human synthetic
Aβ1-42, and, 1 hour after treatment, cell lysates were subjected
to Western analysis using an anti-Aβ antibody (BAM-10) (A).
B. Quantification (the band density ratio of human Aβ1-42 to actin,
with n = 3 for each group) One-way ANOVA followed by post-hoc
comparison revealed significant differences between each of the
cytokine treatment conditions compared to control (for IL-4 versus
control, p < 0.05; for all others, p ≤ 0.01).
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critical role in loading and transporting of extracellular pathogens and toxins (as
immunogenic MHC II-peptide complexes) to the APC surface, where they are recognized
by CD4+ T-cells (Chow, 2002). MHC II is particularly interesting, as microglial cells
express it in the frontal cortex and hippocampus of normal aging individuals, and
expression levels are markedly increased in these brain regions in AD cases (Perlmutter,
1992). The impairment of MHC II function results in a significant reduction of
microglia-associated CNS inflammation (including multiple sclerosis and AD)
(Perlmutter, 1992; Liew, 1994), suggesting that MHC II plays an important role in
regulation of microglial immune responses. In addition, effects of CD40 ligation on
promotion of the microglial MHC II-mediated APC processes have been also reported
(Matyszak, 1999; Aloisi, 2000; O’keefe, 2002). We wished to investigate whether the
CD40-CD40L interaction could promote formation of immunogenic MHC II-Aβ peptide
complexes in cultured microglial cells. We treated microglial cells with CD40L protein
(2 µg/mL) the presence or absence of “aged” PE-Aβ1-42 peptide (50 nM) for 60 min (in
pilot studies, we evaluated various time points from 30-180 min, and found that the 60min time point allowed optimal co-localization of MHC II and Aβ peptide as measured
by immunoprecipitation/Western blot and fluorescence microscopy) (data not shown).
To examine the co-localization of MHC II and Aβ peptide, we performed
immunofluorescence staining on these cells using FITC-conjugated anti-mouse MHC II
antibody. Results show that CD40 ligation promotes MHC II-Aβ peptide complex
formation as detected by fluorescence microscopy (Figure 22a and b). To further
evaluate these effects we treated primary microglial cells in parallel with CD40L protein
(2 µg/mL) in the presence or absence of “aged” Aβ1-42 (3 µM) for 60 min. Cell lysates
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were then prepared, immunoprecipitated with anti-mouse MHC II antibody, and
subjected to Western blotting using anti-human Aβ antibody (BAM-10). As shown in
Figure 22c, data show that CD40 ligation results in promotion of MHC II-loaded
Aβ peptide. Taken together, these data demonstrate that CD40 signaling plays an
important role in promotion of a MHC II-Aβ complex.

5.2.5 Microglial MHC II-Aβ peptide complex is functional
In order to further evaluate the functionality of CD40L-stimulated MHC II-Aβ peptide
complex, we established primary cultures of splenocytes from C57BL/6 mice immunized
with Aβ1-42 peptide. We then isolated CD4+ T-cells from these splenocytes and
performed an antigen presentation assay as detailed in Materials and Methods. Briefly,
microglial cells were pre-treated with Aβ1-42 (1 µM) in the presence or the absence of
CD40L protein (2 µg/mL) for 6 h prior to co-culture with Aβ-immunized mouse-derived
CD4+ T-cells. Thirty-six hours after co-culture, the resulting co-cultured supernatants
were collected for analysis of cytokines. As shown in Figure 23, levels of T-cell-derived
cytokines (including IFN-γ and IL-2) and microglia-derived cytokines (TNF-α and IL-6)
were significantly elevated in the co-treated condition (CD40L plus Aβ1-42) compared to
controls, demonstrating that this condition stimulates both microglial APC function and
T-cell activation. Furthermore, to test whether this effect could be specifically dependent
on the CD40-CD40L interaction, we pre-incubated microglial cells with antagonist antiCD40 antibody (2.5 µg/mL) for 1 h and repeated the antigen presentation assay as
described above. Results show that stimulation of microglia and T-cell activation is
markedly attenuated as evidenced by decreased secretion of IFN-γ, IL-2, TNF-α and IL-6
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Figure 22.
CD40 ligation promotes formation of microglial MHC II-Aβ peptide complex.
A and B. Primary cultured microglial cells were treated with “aged” PE-Aβ1-42
peptide in the presence or absence of CD40L and stained with FITC-anti-mouse
MHC II antibody. Left panel shows MHC II positive; central panel shows Aβ
positive; right panel shows the co-localization of MHC II and Aβ. C. CD40
ligation results in enhanced MHC II-loaded Aβ. To validate MHC-II and Aβ
peptide co-localization, microglia were treated as in (A) but the lysates were
subjected to I\immunoprecipitation using anti-mouseMHC II antibody and
Western blotting using anti-human Aβ antibody (BAM-10). D. Cell lysates
were probed for actin and Aβ to demonstrate equal loading.
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production (Fig. 23 and 24), suggesting that CD40 signaling is necessary for microglial
APC phenotype function in the context of Aβ.

5.3 Discussion
We have previously shown that interaction of CD40 with CD40L enables microglial
activation in vitro in response to Aβ peptides (Tan, 1999). This finding was validated in
vivo by the observation of decreased microgliosis in transgenic mice overproducing Aβ,
but deficient in CD40L (Tan, 2002). Furthermore, reduced microgliosis in these mice
was associated with marked reduction in cerebral Aβ levels and Aβ plaque load.
However, not all forms of microglial activation are deleterious, as activated microglia
may serve a protective role in immunotherapeutic strategies for AD (Rogers, 2002;
Wyss-coray, 2001; Schenk, 1999). Here we suggest a model for microglial activation
(Figure 25) that addresses its seemingly controversial role as both potentially therapeutic
as well as pathogenic in AD. This model finds many parallels with the activation of
innate immune cells (i.e. macrophages and dendritic cells) in the periphery and is further
supported by numerous studies that have already described the plasticity of CNS
microglial cells as well as their pleiotrophic presentation once activated (Santambrogio,
2001; Nakamura, 2002). Our model suggests that microglial cells exist in at least two
functionally discernable states once “activated”, namely a phagocytic phenotype or an
antigen presenting phenotype, as governed by their co-stimulatory environment. In the
phagocytic phenotype, microglial function to engulf and degrade extracellular debris or
foreign bodies. We suggest that this property of the phagocytic phenotype is associated
with the reported benefits of activated microglial cells in AD. Conversely, switching to
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Figure 23.
Microglial MHC II-Aβ peptide complex is functional.
Microglial cells were pre-treated with Aβ1-42 alone or in presence
of antagonist anti-CD40 antibody in the presence or the absence
of CD40L protein for 6 h and then co-cultured with Aβ-immunized
mouse-derived CD4+ T-cells for 36 h. The resulting supernatants
were collected for analysis of cytokines. Data are represented as pg of
cytokine/mg of total cellular protein (mean +/- 1 SD). One-way ANOVA
followed by post-hoc comparison revealed a significant difference
between Aβ treatment and Aβ/CD40L co-treatment condition (p<0.001),
and between Aβ/anti-CD40/CD40L co-treatment to Aβ/control
IgG/CD40L co-treatment (p<0.05).
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Figure 24.
Microglial MHC II-Aβ peptide complex is functional.
Microglial cells were pre-treated with Aβ1-42 alone or in presence
of antagonist anti-CD40 antibody in the presence or the absence
of CD40L protein for 6 h and then co-cultured with Aβ-immunized
mouse-derived CD4+ T-cells for 36 h. The resulting supernatants
were collected for analysis of cytokines. Data are represented as pg of
cytokine/mg of total cellular protein (mean +/- 1 SD). One-way ANOVA
followed by post-hoc comparison revealed a significant difference
between Aβ treatment and Aβ/CD40L co-treatment condition (p<0.001),
and between Aβ/anti-CD40/CD40L co-treatment to Aβ/control
IgG/CD40L co-treatment (p<0.05).
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Figure 25.
Schema of stages microglial activation. (a) Whether in
the brain or when isolated in culture, resting microglia display a
ramified morphology and express distinct cells surface markers
(i.e. CD11b, c; B71, 2; CD45 low, high; MHC II; CD40). Upon
activation they rapidly proliferate and take on a more amoeboid
appearance (b, c). Importantly, we suggest that the activated state
is comprised of at least two functionally distinct phenotypes. In
the phagocytic phenotype (b), cell surface mediators of microglial
phagocytic function increase markedly. Noteworthy is the increase
in scavenger receptor (SR), complement receptors and Fc receptors.
In the presence of co-stimuli (i.e. CD40L), this activation proceeds
to the APC phenotype (c) where phagocytic potential declines in
lieu of pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
concomitant with antigen presentation in the context of MHC II.
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the APC phenotype blocks this phagocytic ability and elicits the release of proinflammatory cytokines leading to chronic microgliosis, which may act to exacerbate
AD-like pathology (Frackowiak, 1992).
We have previously demonstrated that co-activation of the CD40 signaling
pathway potentiates Aβ stimulation of microglial TNF-α production (Tan, 1999). In this
study, we extend on our earlier finding by showing that the CD40-CD40L interaction can
dynamically govern the switch from the phagocytic to the antigen presenting phenotype
of activated microglial cells in vitro. In particular, we observe that co-incubation with
Aβ and CD40L protein inhibits microglial uptake and removal of exogenous Aβ peptides
while evoking the release of Th1-type cytokines. We further demonstrate that these Th1cytokines can directly inhibit microglial phagocytosis of exogenous Aβ peptide. This
suggests a positive feedback mechanism whereby microglial products of the APC
phenotype drive activation away from anti-inflammatory phagocytosis and towards proinflammatory antigen presentation. Consistent with this view, we report increased
microglial MHC II-Aβ peptide complexes following CD40 ligation in the presence of
exogenous Aβ peptide. This suggests that, following CD40 ligation, the phagocytosed
Aβ peptide is being directed away from clearance mechanisms (i.e. lysosomal pathway)
towards MHC II loading and presentation. Moreover, we demonstrate that these MHC
II-Aβ peptide complexes are functional as they mediate T-cell activation. This may of be
particular importance in immunotherapeutic strategies for AD, as preliminary evidence
from the recently halted Aβ1-42 vaccination clinical trails suggest that Aβ peptide
presentation by APCs may have contributed to the invading T-cell induced
meningoencephalitis seen in some of the patients (Ferrer, 2004).
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Interestingly, besides the established signaling cascade initiated by CD40 ligation,
the CD40 receptor has been shown to directly ensure surface binding and uptake of heat
shock protein-70 (HSP) associated proteins (Becker, 2002). In fact, HSP-70 associated
proteins have been previously shown to bind Aβ peptides and facilitate their phagocytosis
and clearance by microglial cells (Kakimura, 2002). However, as we have not directly
assessed the role of endogenous HSP associated proteins in this study, it remains to be
determined to what extent they impact the phenomenon that we have described here,
specifically microglial CD40 signaling induced switching from phagocytic to APC
phenotype in the context of exogenous Aβ peptides.
In summary we suggest that some of confusion about the role of microglial
activation, in general, may be remedied if one considers that the term “activation” when it
is applied to microglial cells, probably represents at least two functionally distinct states.
Moreover, we provide data that suggests CD40 signaling pathway stimulation as one of
the mechanisms by which “activated” microglial cells are converted from the phagocytic
phenotype to the antigen presenting phenotype. With respect to the microgliosis
occurring in AD, we suggest that therapeutic interventions that promote the phagocytic
phenotype of “activated” microglia might thus avoid the unwanted sequelae of the APC
phenotype and slow progression of the disease.
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